[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fujian Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":661},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,47,80,107,133,159,184,211,238,260,285,314,340,374,401,429,458,479,500,527,549,571,596,616,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642750","phase-2-ql1706-combined-with-standard-therapy-for-conversion-therapy-of-synchronous-liver-metastases-from-colon-cancer-a-multicenter-single-arm-exploratory-study-100642750",false,"NCT07649473","QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","Inclusion Criteria:\n\n* Aged 18 to 70 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Histologically or cytologically confirmed colon adenocarcinoma, with pathologically or radiographically verified liver-only metastases.\n* Microsatellite stable (MSS) \u002F proficient mismatch repair (pMMR) confirmed by immunohistochemistry (IHC) or polymerase chain reaction (PCR).\n* No prior local or systemic anti-tumor therapy for colon cancer liver metastases, including but not limited to targeted therapy, immunotherapy, systemic or hepatic arterial infusion chemotherapy, radiotherapy and surgery.\n* Inclusion criteria for liver metastases: ① More than 5 liver metastatic lesions, with at least one lesion measuring less than 3 cm in diameter; ② Child-Pugh Class A; ③ Future Liver Remnant (FLR) \u002F Standard Liver Volume (SLV) \\> 30% for patients without liver cirrhosis, or \\> 40% for patients with liver cirrhosis; ④ Exclude lesions involving complicated surgical sites, such as biliary tract reconstruction, vascular reconstruction, invasion of hepatic hilum, portal vein or inferior vena cava.\n* At least one radiographically measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).\n* Expected survival of no less than 12 weeks.\n* Laboratory test results meet the following criteria within 7 days prior to the first study drug administration (No blood products, hematopoietic growth factors, albumin or other corrective medications deemed necessary by the investigator shall be administered within 14 days before testing):\n\n  1. Biochemistry: Alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with liver metastases; Total bilirubin (TBIL) ≤ 1.5 × ULN, or ≤ 2 × ULN in patients with liver metastases; Serum creatinine ≤ 1.5 × ULN, or creatinine clearance \\> 50 mL\u002Fmin (calculated via Cockcroft-Gault formula).\n  2. Hematology: Hemoglobin (Hb) ≥ 9.0 g\u002FdL; No red blood cell transfusion within 1 week (including the test day) before baseline Hb test; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; No platelet transfusion within 1 week (including the test day) before baseline platelet test.\n  3. Coagulation function: International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (no bleeding within the past 14 days), INR ≤ 2 × ULN and APTT within normal range.\n  4. Urinalysis: Urinary protein ≤ 30 mg\u002FdL (1+) by dipstick or routine urinalysis. If urine protein ≥ 2+, 24-hour urinary protein quantification shall be less than 1 g\u002F24h.\n* No contraindications to radiotherapy, chemotherapy or immunotherapy.\n* For female subjects of childbearing potential: serum pregnancy test must be negative within 7 days prior to enrollment. They must agree to use effective contraception throughout the study and for 5 months after the last study drug administration. Male subjects with partners of childbearing potential must also use effective contraception during the study and for 5 months after the last dose. Lactating women are excluded.\n* Subjects must be fully informed of the study prior to enrollment, voluntarily sign the written informed consent form, and be willing and able to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n* Confirmed non-adenocarcinoma pathological types via histopathology or cytopathology, including squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc. For mixed pathological types, eligibility is determined by the predominant component; patients are eligible only if a pathologist confirms the adenocarcinoma component accounts for more than 70%. Patients with primary appendiceal tumors are excluded.\n* Presence of distant metastases at sites other than the liver.\n* Prior systemic treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies or other immunotherapeutic agents, or the CAPOX regimen. Prior radiotherapy for liver metastases, or prior radiation exposure to normal liver tissue adjacent to the planned irradiation field.\n* History of other malignant tumors within 5 years prior to enrollment, except cured carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, radically treated localized prostate cancer, and radically treated ductal carcinoma in situ.\n* Active autoimmune diseases requiring systemic treatment (with immunomodulators, corticosteroids or immunosuppressants) within the past 2 years. Replacement therapies such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency are permitted and not regarded as systemic immunosuppressive treatment.\n* Immunodeficiency, or receipt of long-term systemic corticosteroids (prednisone equivalent \\> 10 mg per day) or other immunosuppressants within 7 days before enrollment or anticipated during study treatment.\n* Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites.\n* Tumor-related complications such as bleeding, perforation or intra-abdominal infection within 3 months prior to enrollment.\n* Clinically significant bleeding symptoms or high bleeding risk within 3 months prior to enrollment, including gastrointestinal hemorrhage, gastroesophageal varices, bleeding gastric ulcer, hematochezia, hematemesis or hemoptysis. Presence of gastrointestinal disorders including active peptic ulcer, ulcerative colitis, gastrointestinal perforation, unhealed gastrointestinal fistula, malabsorption syndrome or uncontrolled inflammatory bowel disease.\n* Thrombotic or thromboembolic events including cerebrovascular accident, pulmonary embolism and deep vein thrombosis within 6 months prior to enrollment.\n* Medical history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonia or interstitial lung disease; or evidence of active pneumonia detected on contrast-enhanced chest CT.\n* Any significant clinical or laboratory abnormalities judged by the investigator to compromise safety assessment, including uncontrolled active infection, poorly controlled diabetes, hypertension unresponsive to single-agent therapy, Grade ≥ 2 peripheral neuropathy, congestive heart failure, New York Heart Association (NYHA) Class ≥ II cardiac disease, myocardial infarction within 3 months prior to enrollment, unstable arrhythmia, unstable angina, chronic kidney disease and thyroid dysfunction.\n* Major surgery performed within 28 days prior to enrollment without complete postoperative recovery.\n* Active infection requiring systemic oral or intravenous treatment within 2 weeks prior to enrollment (excluding viral hepatitis and prophylactic medication).\n* Patients with active tuberculosis, or those who received anti-tuberculosis therapy within 1 year prior to enrollment.\n* For patients positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), HBV-DNA must be less than 500 IU\u002FmL. Patients with active hepatitis B must have received antiviral therapy for at least 14 days before enrollment (e.g., entecavir or tenofovir per local guidelines) and agree to continue effective antiviral treatment throughout the study. For patients positive for HCV antibody, HCV-RNA testing is required; those with HCV-RNA \\> 1000 copies\u002FmL will be excluded.\n* Positive human immunodeficiency virus (HIV) antibody.\n* Administration of any live vaccine (e.g., influenza vaccine, varicella vaccine) within 28 days prior to enrollment.\n* Prior allogeneic bone marrow transplantation or solid organ transplantation.\n* Known allergy to any study drug or its excipients.\n* History of uncorrected serum electrolyte disorders (e.g., hypokalemia, hypocalcemia, hypomagnesemia).\n* Participation in other interventional clinical studies within 28 days prior to enrollment.\n* Presence of clinically significant underlying diseases or other conditions judged by the investigator to interfere with study drug administration or protocol compliance.","ALL","18 Years","70 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single-arm clinical study aiming to enroll 30 colon cancer patients with liver-only metastases. All eligible participants will undergo screening and enrollment after signing the informed consent form.\n\nAll patients will receive stereotactic body radiation therapy (SBRT) targeting 1 to 3 liver lesions (each \\\u003C 3 cm) at a total dose of 50 Gy delivered in 5 fractions. For lesions adjacent to the liver capsule, portal vein or bile duct, the target volume can be expanded by 5-10 mm outside the visible lesion boundary. One week after radiotherapy completion, patients will be treated with QL1706 (Apalitamab-Tovorizumab, 5 mg\u002Fkg, iv, Q3W) combined with CAPOX plus bevacizumab.\n\nPreoperative treatment consists of up to 6 cycles, with each cycle lasting 3 weeks. Efficacy assessment will be conducted every 2 cycles. The investigator or multidisciplinary team (MDT) will decide to initiate curative treatment (surgical resection or radiofrequency ablation of liver metastases, combined with synchronous or staged resection of primary colon lesion) or continue conversion therapy. Surgery shall be scheduled 6 weeks after the final dose of bevacizumab. During the preoperative waiting period, one extra cycle of QL1706 (5 mg\u002Fkg, iv, Q3W) plus CAPOX is permitted. The interval between the last immunochemotherapy administration and surgery is required to be 2-3 weeks.\n\nAdjuvant therapy is scheduled to start 3 weeks after surgery, and must be initiated no later than 2 months postoperatively. The investigator will determine the use of QL1706 and\u002For bevacizumab in adjuvant setting according to individual patient conditions. If the time from surgery to adjuvant therapy is less than 4 weeks, the first postoperative cycle will use QL1706 (5 mg\u002Fkg, iv, Q3W) combined with CAPOX only. Postoperative QL1706 maintenance treatment will not exceed 1 year. Patients receiving postoperative systemic adjuvant chemotherapy will complete 8 cycles of perioperative CAPOX with or without bevacizumab.\n\nPatients with progressive disease (PD) or those who fail conversion therapy within 18 weeks will switch to alternative systemic regimens in accordance with the 2025 guidelines issued by the Chinese Society of Clinical Oncology (CSCO) and the National Comprehensive Cancer Network (NCCN).\n\nCAPOX + bevacizumab regimen (repeated every 3 weeks):\n\nOxaliplatin: 130 mg\u002Fm², intravenous infusion over 2 hours, d1; Capecitabine: 1000 mg\u002Fm² per dose, po, bid, d1-14; Bevacizumab: 7.5 mg\u002Fkg, ivgtt, d1.",[27,28],"Colon Cancer","Synchronous Liver Metastases",[30,31,32,33],"QL1706","colon cancer","synchronous liver metastases","conversion","NOT_YET_RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":21},"2026-08-15",{"date":42,"type":21},"2033-12-31",{"name":44,"class":45},"Fujian Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100640274","dementia-management-training-programme-for-primary-health-care-providers-100640274","NCT07617883","Dementia Management Training Programme for Primary Health Care Providers","Application and Effectiveness of a RE-AIM-Based Dementia Management Competency Training Program for Primary Health Care Providers: A Cluster Randomized Controlled Trial","Inclusion Criteria:\n\nPrimary healthcare workers aged 18 years or older\n\nRegistered healthcare professionals holding a formal license issued by the national health authority\n\nAt least 1 year of work experience\n\nAble to access the internet using a computer, tablet, or mobile phone\n\nCurrently working in a participating community health service center or township health center\n\nWilling to participate in the study and provide written informed consent\n\nExclusion Criteria:\n\nPersonnel who do not directly participate in patient disease management, including logistics or auxiliary staff\n\nInterns, trainees, or students\n\nIndividuals currently participating in other similar dementia training interventions\n\nIndividuals planning to leave their current institution within the next 12 months\n\nIndividuals who refuse to participate in the study or decline to provide written informed consent",true,{"count":56,"type":21},240,[58],"NA","This study aims to evaluate the effectiveness and implementation outcomes of a dementia management competency training program for primary healthcare workers. A cluster randomized controlled trial will be conducted among primary healthcare institutions in Nanping, Fujian Province, China. Eligible primary health care providers will be recruited from community health service centers and township health centers.Participating institutions will be randomized in a 1:1 ratio to either a structured dementia management training group or a self-directed learning control group. The intervention group will receive a 12-week blended training program, including online learning, an in-person skills workshop, and case-based practice supervision. The control group will receive self-directed online learning materials. Outcomes will be assessed at baseline, immediately after the intervention, and 3 months after the intervention. The primary outcome is the change in dementia knowledge, measured using the Dementia Knowledge Assessment Scale. Secondary outcomes include dementia-related attitudes, dementia management practice competency, self-reported dementia management behaviors, objective screening and referral-related indicators, and implementation outcomes based on the RE-AIM framework.",[61,62],"Dementia","Primary Health Care Providers",[64,65,66,67,68,69,70,71],"dementia","primary health care providers","dementia management","training","cluster randomized controlled trial","RE-AIM","implementation science","primary care","2026-06-01",{"date":74,"type":38},"2026-06-03",{"date":76,"type":21},"2026-06-15",{"date":78,"type":21},"2026-12-15",{"name":44,"class":45},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100638805","computer-vision-based-recognition-of-parathyroid-glands-and-recurrent-laryngeal-nerves-in-endoscopic-surgery-100638805","NCT07628543","Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery","Prospective Multicenter Model Validation Study of the PTAIR Computer Vision Model for Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves During Endoscopic Thyroid Surgery","PTAIR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with benign or malignant thyroid disease who are scheduled to undergo endoscopic thyroid surgery.\n3. Standardized recorder-based intraoperative video collection is planned during surgery.\n4. Patients agree to intraoperative video recording, de-identification, and research use.\n5. Basic perioperative clinical data are available.\n6. The participating center is able to follow the standardized procedures for video collection, data upload, data security, and annotation quality control.\n\nExclusion Criteria:\n\n1. Refusal to provide informed consent.\n2. Patients scheduled to undergo conventional open thyroid surgery.\n3. Standardized recorder-based intraoperative video collection cannot be performed.\n4. Intraoperative video quality is insufficient for model analysis or expert review.\n5. Key surgical phases are missing from the video recording.\n6. Expert annotation or review of the parathyroid glands or recurrent laryngeal nerves cannot be completed.\n7. Video de-identification fails.\n8. Severe missing perioperative clinical data.\n9. Other conditions judged by the investigators to be unsuitable for study inclusion.",{"count":89,"type":21},100,"OBSERVATIONAL","This study aims to evaluate the performance of the PTAIR computer vision model for recognizing parathyroid glands and recurrent laryngeal nerves during endoscopic thyroid surgery. Multicenter intraoperative endoscopic surgery videos will be prospectively collected. Using the video recorder timeline as the unified time reference, the first recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR, junior physicians, and senior physicians will be recorded during surgery. The continuous recognition time of parathyroid glands and recurrent laryngeal nerves by PTAIR will also be recorded.\n\nThis study focuses on the recognition performance of PTAIR in real-world multicenter endoscopic thyroid surgery settings. At this stage, PTAIR will not be used to guide intraoperative surgical decision-making, and the study will not evaluate the effect of PTAIR on clinical outcomes. The collected video data will be used to assess the performance of PTAIR under different centers, surgeons, equipment conditions, and surgical field conditions, and may provide data support for future model optimization.",[93,94],"Thyroid Diseases","Thyroid Neoplasms",[86,96,97,98,99,100],"Computer Vision","Endoscopic Thyroid Surgery","Parathyroid Gland Recognition","Recurrent Laryngeal Nerve Recognition","Model Validation",{"date":102,"type":38},"2026-06-05",{"date":72,"type":21},{"date":105,"type":21},"2028-05-31",{"name":44,"class":45},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":16,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":46},"100599227","dyadic-personalized-home-based-activity-program-for-mild-to-moderate-dementia-patients-post-discharge-100599227","NCT07081750","Dyadic Personalized Home-Based Activity Program for Mild-to-Moderate Dementia Patients Post-Discharge","Construction and Efficacy Evaluation of a Dyadic Personalized Home-Based Activity Intervention Program for Patients Discharged With Mild to Moderate Dementia and Behavioral and Psychological Symptoms","Inclusion Criteria Patients\n\n* Be aged ≥ 60 years;\n* Have a diagnosis of dementia according to ICD-10 criteria, with a Clinical Dementia Rating (CDR) score of 1-2 (mild-to-moderate stage);\n* Retain basic verbal communication ability;\n* Present at least one neuropsychiatric symptom (a score ≥ 1 on any single item) within the past month, as evaluated by the Neuropsychiatric Inventory (NPI);\n* Be medically fit for hospital discharge and scheduled to receive home care post-discharge;\n* Be willing to participate in this study and provide written informed consent.\n\nFamily Caregivers\n\n* Be aged ≥ 18 years;\n* Have kinship with the patient (e.g., spouse, children, siblings, etc.);\n* Undertake primary care responsibilities on an unpaid, non-professional basis, and have the longest average daily care hours among all family caregivers;\n* Be willing to assume continuous home care responsibilities for at least 3 months post-discharge;\n* Have intact verbal communication skills;\n* Possess basic proficiency in operating the WeChat application (a widely used social communication application in China), including independently sending and receiving messages, as well as making voice and video calls；\n* Be willing to participate in this study and provide written informed consent.\n\nExclusion Criteria Patients\n\n* Have severe somatic diseases (e.g., malignant tumors, heart failure, physical disabilities) or severe psychiatric disorders;\n* Have severe visual or hearing impairment;\n* Have dementia secondary to the following conditions: central nervous system diseases (e.g., encephalitis, brain tumors, epilepsy, multiple sclerosis, Parkinson's disease), nutritional and metabolic disorders (e.g., thyroid dysfunction, vitamin B12 or folate deficiency), substance or alcohol dependence, and other potential causes of secondary dementia;\n* Suffer from severe physical or mental disorders, extreme debilitation, long-term bedridden status, end-stage disease with a life expectancy of less than six months, or be unable to cooperate with or tolerate the study intervention;\n* Be enrolled in any other clinical research that may interfere with the outcomes of this study.\n\nFamily Caregivers\n\n* Have severe somatic diseases (e.g., malignant tumors, heart failure, physical disabilities) or severe psychiatric disorders;\n* Have severe visual or hearing impairment;\n* Be enrolled in any other clinical research that may interfere with the outcomes of this study.","60 Years",{"count":116,"type":21},55,[58],"This interventional study aims to evaluate the efficacy of a dyadic personalized home-based activity program in managing behavioral and psychological symptoms of dementia (BPSD) among home-dwelling people living with mild-to-moderate dementia post-discharge. The main question it aims to answer is:\n\nDoes the dyadic personalized home-based activity program significantly reduce BPSD in individuals post-discharge with mild-to-moderate dementia?\n\nResearchers will compare individuals living with mild to moderate dementia who are receiving routine care to see if the dyadic personalized home-based activity program is effective for BPSD.\n\nParticipants will:\n\n1. In-hospital stage: A personalized home-based activity intervention plan is tailored for patients. Family caregivers receive professional training on care skills related to home-based activities and are provided with corresponding activity resources and support.\n2. Post-discharge home-based stage: The intervention is delivered by family caregivers for a total of 12 weeks. The intervention is recommended to be performed twice per week, with each session lasting about 30 minutes in accordance with the patient's individual tolerance. Intermittent rest is advised (e.g., a 2-3 minute break every 10 minutes). The weekly intervention frequency and session duration can be flexibly adjusted according to the family caregivers' schedule and the patient's condition, including mood fluctuations and physical discomfort. Family caregivers are required to record the patient's activity participation, subjective feelings and behavioral responses, and submit regular feedback to the research team. Based on feedback from patients and family caregivers, the research team will conduct dynamic adjustments and continuous optimization of the intervention program throughout the study.",[61],[64,121,122,123],"behavioral and psychological symptoms","home-based","activity","RECRUITING","2026-05-06",{"date":127,"type":38},"2026-05-11",{"date":129,"type":38},"2025-07-20",{"date":131,"type":21},"2026-06-30",{"name":44,"class":45},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":16,"minAge":139,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100630714","phase-1-clinical-study-of-universal-cd19-car--t-cell-infusion-in-the-treatment-of-relapsedrefractory-acute-b-lymphoblastic-leukemia-100630714","NCT07491263","Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed\u002FRefractory Acute B Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Age \\> 14 years, gender unrestricted;\n* Clinically diagnosed with relapsed\u002Frefractory acute B-lymphoblastic leukemia, with bone marrow blast\u002Fimmature lymphocyte proportion ≥5% (morphology) (excluding cases with isolated extramedullary involvement), meeting any of the following criteria:\n\n  1. Failure to achieve CR after 2 cycles of standard chemotherapy;\n  2. Initial induction achieved CR, but CR duration ≤12 months;\n  3. Relapsed\u002Frefractory B-ALL refractory to first or multiple salvage therapies;\n  4. Post-hematopoietic stem cell transplantation relapse, including hematological relapse and minimal residual disease (MRD) positivity;\n  5. Patients for whom no standard therapy exists.\n* Cytology or histology confirms tumor cell immunophenotype as CD19-positive;\n* Expected survival time exceeding 3 months;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;\n* Key organ functions meeting the following criteria: left ventricular ejection fraction ≥50% by echocardiography; serum creatinine ≤1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN; total bilirubin ≤1.5 × ULN;\n* Negative pregnancy test for women of childbearing potential; both males and females agree to use effective contraception during treatment and for 1 year thereafter;\n* Toxicity from prior anti-tumor therapy ≤ Grade 1 (according to CTCAE v5.0) or at an acceptable level per inclusion\u002Fexclusion criteria;\n* No significant hereditary diseases;\n* Able to comprehend the trial requirements and procedures, and willing to participate in the clinical study as required;\n* Signed informed consent form for the trial\n\nExclusion Criteria:\n\n* Presence of central nervous system (CNS) involvement or a clinically significant history of CNS diseases, such as epilepsy and cerebrovascular diseases;\n* Pregnant or lactating women, or women who disagree to use effective contraception during treatment and within 1 year after treatment;\n* Other malignancies that are not in remission;\n* Patients with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy;\n* Patients who have received allogeneic immune cell therapy within 6 months before enrollment, or donor lymphocyte infusion within 6 weeks before enrollment;\n* Confirmed positive anti-FMC63 and DSA responses in the patient's serum;\n* Patients who have participated in other clinical trials within 4 weeks before enrollment;\n* Uncontrolled infectious diseases or other serious conditions, including but not limited to infections (human immunodeficiency virus, acute or chronic active hepatitis B or C), congestive heart failure, unstable angina, arrhythmia, or conditions considered by the treating physician to pose unpredictable risks;\n* History of stroke or intracranial hemorrhage within 3 months before enrollment;\n* Major surgery or trauma within 28 days before enrollment, or main side effects not yet recovered;\n* History of allergy to any component of the cell product;\n* Inability to understand or unwillingness to sign the informed consent form;\n* Other reasons deemed by the researchers as unsuitable for the clinical trial.","14 Years",{"count":141,"type":21},6,[143],"PHASE1","This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell infusion in subjects with CD19-positive R\u002FR B-ALL.",[146],"Relapsed\u002FRefractory CD19-positive B-ALL",[148,149,150],"CD19","CAR-γδT","cell therapy","2026-03-18",{"date":153,"type":38},"2026-03-24",{"date":155,"type":21},"2026-05-01",{"date":157,"type":21},"2028-12-31",{"name":44,"class":45},{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":16,"minAge":139,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100625230","response-to-neoadjuvant-treatment-in-locally-advanced-thyroid-cancer-100625230","NCT07419932","Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study","NeoLATC","Inclusion Criteria:\n\n* Age ≥ 14 years at enrollment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Histologically or cytologically confirmed thyroid carcinoma, including differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC).\n* LATC defined as clinical stage T4N0-1 at baseline, as confirmed by a multidisciplinary thyroid oncology board.\n* For patients with distant metastasis, the potential benefit from surgical intervention must be documented by the treating team.\n* Presence of at least one measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Normal function of major organs.\n* Written informed consent obtained.\n\nExclusion Criteria:\n\n* Patients who refuse tumor tissue biopsy or surgery.\n* Prior thyroid or major neck surgery.\n* History of other treatments for cancer, including surgery, chemotherapy, radiotherapy, or molecular targeted therapy, that may affect the current treatment plan.\n* Concurrent active malignancies.\n* Uncontrolled systemic diseases, including diabetes, hypertension, etc.\n* Pregnancy or breastfeeding.","80 Years",{"count":169,"type":21},120,"This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.",[172,94],"Thyroid Cancer",[172,174,175],"locally advanced","Neoadjuvant Therapy","2026-02-12",{"date":178,"type":38},"2026-02-19",{"date":180,"type":38},"2025-12-23",{"date":182,"type":21},"2029-06-30",{"name":44,"class":45},{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100622460","remote-ischemic-preconditioning-for-aute-type-a-aortic-dissection-surgery-100622460","NCT07383909","Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery","Evaluation of the Organ-Protective Effects of Remote Ischemic Preconditioning in Patients Undergoing Surgery for Acute Type A Aortic Dissection: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years, with no restriction on sex;\n2. Diagnosis of acute Type A aortic dissection requiring emergency surgery (symptom onset \\\u003C14 days);\n3. Ability to understand the study objectives, voluntary provision of written informed consent by the patient or a legally authorized representative, and willingness to comply with follow-up.\n\nExclusion Criteria:\n\n1. Traumatic or iatrogenic aortic dissection;\n2. Previous open cardiac or thoracic aortic surgery;\n3. Severe preoperative dysfunction of vital organs, such as persistent deep coma, abdominal compartment syndrome, or circulatory failure;\n4. Severe comorbidities, including myocardial infarction within the past 7 days, stroke within the past 2 months; end-stage renal disease (eGFR \\\u003C30 ml\u002Fmin\u002F1.73 m²); end-stage liver disease (total bilirubin \\>342 μmol\u002FL or INR \\>2.0);\n5. Evidence of ischemia in the limb planned for intervention, such as decreased skin temperature, pain, pallor, with or without sensory disturbance, paralysis, or diminished\u002Fabsent pulses; or severe deformity or prior arteriovenous surgery at the intervention site;\n6. Peripheral arterial disease involving the limbs, Raynaud phenomenon, active phlebitis, or a history of deep vein thrombosis of the lower extremities;\n7. Current use of sulfonylurea oral hypoglycemic agents or nicorandil;\n8. Life expectancy \\\u003C1 year (e.g., advanced malignancy);\n9. Participation in another clinical trial without having reached its primary endpoint;\n10. Pregnancy or lactation; immunodeficiency (e.g., HIV positivity, history of organ transplantation); known bleeding disorders, coagulation abnormalities, or sickle cell anemia; active or uncontrolled infection;\n11. Other severe physical or psychiatric disorders, or laboratory abnormalities, which in the investigator's judgment may increase risk or interfere with study outcomes, rendering the patient unsuitable for enrollment.",{"count":192,"type":21},1296,[58],"The goal of this clinical trial is to learn if a technique called remote ischemic preconditioning (RIPC) helps protect organs during emergency surgery for acute type A aortic dissection (ATAAD). The main questions it aims to answer are:\n\nDoes RIPC reduce the risk of major complications after surgery, such as heart, brain, or kidney problems?\n\nIs RIPC safe to use during emergency ATAAD surgery?\n\nResearchers will compare the RIPC group to a control group (who will receive a placebo) to see if RIPC can reduce complications after surgery.\n\nParticipants will:\n\nReceive either RIPC or a sham intervention during their surgery.\n\nBe monitored for up to 30 days after surgery for complications.\n\nHave follow-up visits at 3 months, 1 year, and then yearly for up to 5 years to track their recovery.",[196],"Aortic Dissection Type A",[198,199,200,201],"Remote Ischaemic Conditioning","ischemia reperfusion injury","emergency surgery","major adverse outcomes","2026-01-26",{"date":204,"type":38},"2026-02-03",{"date":206,"type":38},"2026-01-05",{"date":208,"type":21},"2032-12-31",{"name":44,"class":45},3,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":46},"100617098","phase-3-clinical-efficacy-of-adebrelimab-with-or-without-apatinib-mesilate-and-sox-neoadjuvant-therapy-in-locally-advanced-gastric-cancer-100617098","NCT07314203","Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer","SOP-XH-IRB","Inclusion Criteria:\n\n\\*\\*Inclusion Criteria\\*\\* 1. Age 18-75 years (inclusive). 2. Histologically or cytologically confirmed unresectable, locally advanced or metastatic HER2-negative adenocarcinoma of the stomach or gastro-oesophageal junction (GEJ).\n\n3\\. No prior systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy for advanced disease. Subjects who have received prior (neo)adjuvant chemotherapy and\u002For radiotherapy are eligible provided the last dose was completed ≥ 6 months before randomisation.\n\n4\\. At least one measurable lesion per RECIST 1.1 (see Appendix 2). 5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 (see Appendix 4).\n\n6\\. Estimated life expectancy \\> 3 months. 7. Adequate major organ function defined as:\n\n1. Haematology (obtained ≤ 14 days without transfusion):\n\n   1. Hb ≥ 80 g\u002FL\n   2. WBC ≥ 3 × 10⁹\u002FL\n   3. ANC ≥ 1.5 × 10⁹\u002FL\n   4. PLT ≥ 100 × 10⁹\u002FL\n2. Biochemistry:\n\n   1. Total bilirubin \\\u003C 1.5 × upper limit of normal (ULN)\n   2. ALT and AST \\\u003C 2.5 × ULN; ALP ≤ 1.5 × ULN\n   3. Serum creatinine ≤ 1 × ULN and calculated creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault formula) 8. Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrolment and must use highly effective contraception from screening until 8 weeks after the last dose of study drug. Men must be surgically sterile or agree to use effective contraception during the same period.\n\n      9\\. No participation in any other interventional clinical trial during the pre-treatment or on-treatment phases of this study.\n\n      10\\. Voluntary written informed consent obtained; willing and able to comply with study procedures and follow-up.\n\n      Exclusion Criteria:\n\n      Exclusion Criteria\n\n      Subjects meeting any of the following conditions will be excluded from enrollment:\n      1. Known or suspected hypersensitivity to the investigational drug or any drug of the same class.\n      2. Other malignancies within the past 5 years, except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix.\n      3. Currently receiving treatment in another interventional clinical trial, or any systemic anti-gastric-cancer therapy within 4 weeks prior to the first dose.\n      4. Systemic Chinese patent medicines with anti-tumor indications or immunomodulatory agents (e.g., thymosin, interferon, interleukins; local intrapleural use for effusion control is permitted) received within 2 weeks before the first dose.\n      5. Prior exposure to: anti-PD-1, anti-PD-L1, anti-PD-L2, or any agent targeting other T-cell co-stimulatory or co-inhibitory pathways (including but not limited to CTLA-4, OX-40, CD137); or prior chemotherapy including S-1.\n      6. Live-vaccine administration within 4 weeks before enrollment or planned during the study.\n\n         Note: Inactivated seasonal influenza vaccine by injection is allowed within 4 weeks; intranasal live-attenuated influenza vaccine is prohibited.\n      7. Active autoimmune disease requiring systemic therapy (e.g., immunosuppressants, corticosteroids, or disease-modifying agents) within 2 years before the first dose. Replacement therapy (thyroxine, insulin, physiologic glucocorticoids for adrenal or pituitary insufficiency) is not considered systemic therapy.\n      8. Prior allogeneic bone-marrow or solid-organ transplantation.\n      9. Any condition that could impair drug absorption or inability to swallow oral medication.\n      10. Uncontrolled hypertension despite optimal medical management:\n\n          * SBP ≥ 150 mmHg or DBP ≥ 100 mmHg on a single antihypertensive, or requirement of ≥ 2 antihypertensive agents.\n      11. Urinalysis showing proteinuria ≥ 2+ and 24-h urinary protein \\> 1.0 g.\n      12. Active gastro-duodenal ulcer, ulcerative colitis, or other gastrointestinal disorders with bleeding risk; un-resected tumors with active hemorrhage; or any other condition judged by the investigator to predispose to GI bleeding or perforation.\n      13. Significant bleeding tendency within 3 months before enrollment: overt bleeding \\> 30 mL, hematemesis, melena, hematochezia; hemoptysis (\\> 5 mL fresh blood within 4 weeks); or thrombo-embolic event (including stroke\u002FTIA) within 12 months.\n      14. Clinically significant cardiovascular disease:\n\n          * Acute MI, unstable\u002Fsevere angina, or CABG within 6 months before enrollment;\n          * NYHA class \\> II congestive heart failure;\n          * Ventricular arrhythmia requiring therapy;\n          * QTc ≥ 480 ms on baseline ECG.\n      15. Active or uncontrolled severe infection (≥ CTCAE grade 2).\n      16. Known HIV infection; clinically significant hepatic disorders:\n\n          * Chronic hepatitis B with active replication (HBV DNA \\> 1 × 10⁴ copies\u002FmL or \\> 2000 IU\u002FmL);\n          * Hepatitis C with detectable HCV RNA (\\> 1 × 10³ copies\u002FmL);\n          * Other hepatitis or cirrhosis.\n      17. Known dihydropyrimidine dehydrogenase (DPD) deficiency.\n      18. Any condition that, in the opinion of the investigator, would compromise the subject's safety or interfere with study participation.","75 Years",{"count":220,"type":21},118,[222],"PHASE3","Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy",[225,226],"Gastric Cancer","Surgery",[228,229],"gastric cancer","neoadjuvant therapy","2025-12-18",{"date":232,"type":38},"2026-01-02",{"date":234,"type":21},"2026-12-25",{"date":236,"type":21},"2028-08-25",{"name":44,"class":45},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":46},"100616861","a-prospective-single-center-randomized-controlled-clinical-study-evaluating-the-efficacy-and-safety-of-hyperbaric-oxygen-therapy-as-an-adjunctive-treatment-for-chronic-heart-failure-100616861","NCT07311109","A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyperbaric Oxygen Therapy as an Adjunctive Treatment for Chronic Heart Failure","Inclusion Criteria:\n\n1. Diagnostic Criteria\n\n   Diagnosis of chronic heart failure according to the Chinese Guidelines for the Diagnosis and Management of Heart Failure (2024), and meeting the following conditions:\n\n   1.1 Left Ventricular Ejection Fraction (LVEF) ≤ 40% (HFrEF group). 1.2 Presence of chronic HF symptoms (NYHA functional class II-IV) or objective evidence (e.g., elevated natriuretic peptides, structural cardiac abnormalities).\n\n   1.3 Disease duration ≥ 3 months, with no adjustments to the foundational anti-heart failure regimen within the past month.\n2. Age and Informed Consent 2.1 Aged 18 to 70 years (inclusive). 2.2 Understand the study purpose and provide signed informed consent.\n3. Treatment Stability 3.1 Received guideline-recommended, standardized \"New Four Pillars\" anti-heart failure therapy (ARNI\u002FACEI\u002FARB + β-blocker + MRA + SGLT2 inhibitor) for at least 2 weeks prior to enrollment, with no changes in the past month.\n\n3.2 No diuretic dose adjustments within the past 5 days and no clinical signs of fluid overload (e.g., weight gain of ≥ 2 kg\u002Fweek, new-onset pulmonary edema).\n\n\\-\n\nExclusion Criteria:\n\n* Absolute Contraindications\n\n  1. Untreated pneumothorax or pneumomediastinum.\n  2. Claustrophobia, agitation or inability to cooperate, or conditions unsuitable for HBOT such as angle-closure glaucoma or eustachian tube occlusion.\n  3. Unstable vital signs.\n  4. Concurrent intracranial hemorrhage, intracranial mass, malignant tumor, uncontrolled epilepsy, psychiatric disorder, coagulation dysfunction, or other severe uncontrolled comorbidities.\n  5. Severe pulmonary bullae or emphysema.\n  6. Active internal bleeding or coagulopathy.\n  7. Uncontrolled hyperpyrexia (body temperature \\>38.0°C).\n  8. Concurrent use of disulfiram, bleomycin, or cisplatin chemotherapy. Relative Contraindications\n  9. Uncontrolled hypertension (systolic BP \\>160 mmHg or diastolic BP \\>100 mmHg).\n  10. Severe cardiac arrhythmias (e.g., third-degree atrioventricular block without a pacemaker, frequent ventricular tachycardia).\n  11. Chronic obstructive pulmonary disease (FEV1 \\\u003C50% of predicted) or active asthma.\n  12. Psychiatric or cognitive impairment preventing cooperation with the therapy. Comorbidity Restrictions\n  13. End-stage renal disease (dialysis-dependent).\n  14. Terminal malignancy (life expectancy \\\u003C6 months).\n  15. Pregnancy or lactation (a negative pregnancy test is required for women of childbearing potential).\n\n      Recent Clinical Events\n  16. Acute myocardial infarction or unstable angina within the past 4 weeks.\n  17. Hospitalization or emergency department visit for acute heart failure within the past 2 weeks.\n  18. Current use of intravenous positive inotropic agents.\n  19. Within 6 months after cardiac surgery.\n  20. Use of any mechanical circulatory support.\n  21. Participants with a 6-minute walk test result exceeding 450 meters or who are unable to complete the test.\n\n      Other Exclusion Conditions\n  22. Inability to complete follow-up (e.g., planned relocation, non-compliance with follow-up assessments).\n  23. Concurrent participation in any other clinical trial that may interfere with the outcomes of this study.\n  24. Unforeseen circumstances judged by the investigators to be ineligible.",{"count":245,"type":21},150,[58],"This study aims to investigate whether adjunctive hyperbaric oxygen therapy, compared to guideline-directed medical therapy with the \"New Four Pillars\" (ARNI\u002FACEI\u002FARB + β-blocker + MRA + SGLT2 inhibitor) alone, improves cardiac function in patients with chronic heart failure, and to evaluate its efficacy and safety.",[249],"Chronic Heart Failure With Reduced Ejection Fraction",[251,252],"chronic heart failure","HBOT","2025-12-16",{"date":255,"type":38},"2025-12-30",{"date":257,"type":21},"2025-12-15",{"date":157,"type":21},{"name":44,"class":45},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":54,"sex":16,"minAge":114,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":46},"100614087","a-virtual-reality-based-horticultural-planting-program-for-elderly-with-subthreshold-depression-100614087","NCT07275034","A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression","A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression：A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Meets subthreshold depression diagnostic criteria: CES-D score ≥ 16 on the Center for Epidemiological Survey, Depression Scale (CES-D) used in epidemiological surveys (this criterion is widely adopted in comparable studies)\n* No communication barriers in vision, hearing, or speech\n* Informed consent\n\nExclusion Criteria:\n\n* Insulin dependent diabetes\n* Thyroid disease\n* Recent exposure to a major traumatic stress event, with no risk of suicide\n* Currently participating in other similar studies\n* Clinically diagnosed with mental disorders such as depression or schizophrenia\n* Currently taking antidepressant medication\n* Severe cognitive impairment\n* Severe physical illness or organic disorder with impaired self-care abilities",{"count":268,"type":21},36,[58],"Subthreshold depression represents a state of psychological sub-health between normal individuals and clinical depression. It constitutes a high-risk stage for developing clinical depression and a critical phase for alleviating depressive symptoms. However, current research predominantly focuses on treating depression in the elderly, with insufficient attention to interventions for high-risk populations or limited to cross-sectional investigations of subthreshold depression risk factors. Therefore, prioritizing subthreshold depression in the elderly and implementing early interventions is essential. A 2024 article in The Lancet suggests that subthreshold depression treatment should prioritize psychotherapy and lifestyle adjustments over medication. Horticultural therapy, an interdisciplinary approach integrating horticulture, medicine, and psychology, demonstrates unique advantages over traditional medical treatments. In practical application, however, limited resources may hinder adequate support for horticultural activities, compromising activity quality, reducing therapeutic efficacy, and restricting the widespread adoption of horticultural therapy. Integrating VR technology with horticultural therapy can provide patients with more comprehensive, personalized, and effective mental health treatment plans, empowering them toward healthier, more positive lives. Therefore, the research team designed a VR horticultural intervention system for elderly individuals with subthreshold depression based on the Social Participation Competence Framework.",[272],"Subthreshold Depression",[274,272,275,276],"older adults","virutal reality","Gardening","2025-12-09",{"date":279,"type":38},"2025-12-10",{"date":281,"type":21},"2026-02-01",{"date":283,"type":21},"2026-04-20",{"name":44,"class":45},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":313},"100593738","quantitative-intra-operative-assessment-of-parathyroid-perfusion-using-indocyanine-green-icg-fluorescence-imaging-100593738","NCT07010341","Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging","Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence Imaging: A Prospective Observational Study","Inclusion Criteria:\n\n* Scheduled for unilateral thyroid lobectomy plus central (VI-level) lymph-node dissection.\n* Intra-operative findings consistent with:\n* Complete identification and in-situ preservation of the ipsilateral superior parathyroid gland;\n* Complete identification and autotransplantation of the ipsilateral inferior parathyroid gland.\n* Serum 25-hydroxy-vitamin D ≥ 30 ng\u002FmL at baseline; patients below this level may be enrolled after standardized vitamin-D and calcium supplementation with re-test confirming ≥ 30 ng\u002FmL.\n* Surgery and all postoperative follow-up performed at the study center.\n* Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Prior surgery on the thyroid or parathyroid glands.\n* Severe hepatic or renal impairment, or other serious metabolic bone disease.\n* Pregnancy or lactation.\n* Known hypersensitivity to indocyanine green or iodine-containing compounds.\n* Inability or unwillingness to comply with postoperative visits and blood testing.",{"count":293,"type":21},210,"This single-center, prospective, three-phase observational cohort quantifies the relationship between indocyanine green (ICG) fluorescence and early parathyroid function. Adult patients scheduled for unilateral thyroid lobectomy with autotransplantation of the ipsilateral inferior parathyroid gland are enrolled. After intravenous ICG 25 µg\u002Fkg, peak fluorescence of the superior parathyroid gland and the common carotid artery (CCA) is recorded at 60-120 seconds to calculate the ratio R = PTG\u002FCCA. Serum parathyroid hormone (PTH) is measured 30 minutes post-operatively. A derivation cohort (\\~120 patients) generates R-based thresholds for in-situ preservation versus autotransplantation, which are prospectively validated in an independent cohort (60 patients) together with decision-curve analysis of clinical net benefit.",[296],"Thyroid Surgery",[298,299,300,301,302,303,304],"Thyroid surgery","Indocyanine Green","Near-Infrared Fluorescence","Parathyroid Perfusion","Perfusion Threshold","Hypocalcemia","Perfusion Ratio","2025-07-12",{"date":307,"type":38},"2025-07-15",{"date":309,"type":38},"2025-05-01",{"date":311,"type":21},"2026-05-31",{"name":44,"class":45},2,{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":327,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100595524","hybrid-endoscopic-hemithyroidectomy-and-targeted-ablation-for-bilateral-papillary-thyroid-carcinoma-100595524","NCT07033572","Hybrid Endoscopic Hemithyroidectomy and Targeted Ablation for Bilateral Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n* Age 18-65 years.\n* Dominant-side PTC ≤1.5 cm suitable for endoscopic resection.\n* Contralateral nodule ≤7 mm located ≥2 mm from posterior capsule.\n* No radiologic lymph-node metastasis on contralateral side.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Extrathyroidal extension, gross nodal or distant metastasis.\n* Prior neck surgery, prior RFA\u002Fethanol injection, or neck irradiation.\n* Pregnancy or lactation.\n* Serious comorbidities precluding anesthesia or follow-up.","65 Years",{"count":322,"type":21},60,[58],"This study evaluates a thyroid-function-preserving alternative to routine total thyroidectomy for bilateral papillary thyroid carcinoma (PTC). Eligible adults undergo remote-access gas-less axillo-breast endoscopic hemithyroidectomy with level VI dissection on the dominant side, followed by ultrasound-guided radiofrequency ablation (RFA) of a ≤7 mm contralateral focus during the same anesthesia. Outcomes include structural-recurrence-free survival, endocrine-function preservation, safety, and quality of life over 24 months.",[94,326],"Carcinoma, Papillary",[328,329,330,331],"Hybrid endoscopic thyroidectomy","Radiofrequency ablation","Thyroid function preservation","Bilateral Thyroid Carcinoma","2025-07-01",{"date":334,"type":38},"2025-07-03",{"date":336,"type":38},"2018-06-01",{"date":338,"type":21},"2028-06-30",{"name":44,"class":45},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":167,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":46},"100596247","peri-operative-bipap-to-prevent-tracheostomy-in-high-risk-bilateral-vocal-cord-paralysis-bvcp-100596247","NCT07042971","Peri-operative BiPAP to Prevent Tracheostomy in High-Risk Bilateral Vocal-Cord Paralysis (BVCP)","A Multicenter, Randomized Controlled Trial of Pre-operative BiPAP Training and Post-extubation BiPAP Support to Reduce Peri-operative Tracheostomy or Re-intubation in Patients at High Risk for Bilateral Vocal-Cord Paralysis","BVCP-BiPAP","Inclusion Criteria:\n\n* Age 18 - 80 years.\n* Scheduled for thyroidectomy or other neck surgery under general anesthesia.\n* High risk of bilateral vocal-cord paralysis (BVCP) defined by at least ONE of:\n\n  * Pre-operative flexible laryngoscopy showing fixed vocal cords at midline or paramedian position, or glottic gap ≤ 3 mm; OR\n  * Presence of ≥ 2 high-risk factors:\n\n    * Planned bilateral central plus lateral neck dissection\n    * Re-operative bilateral neck surgery or dense scarring\n    * Tumor involving both recurrent laryngeal nerves or crico-arytenoid joints\n    * Severe obstructive sleep apnea (AHI ≥ 30 events\u002Fhour)\n    * Body-mass index (BMI) ≥ 30 kg\u002Fm²\n* Able to tolerate and give informed consent for BiPAP mask use.\n\nExclusion Criteria:\n\n* Emergency surgery or need for immediate tracheostomy.\n* Existing tracheostomy or home ventilator dependence.\n* Inability to protect airway (e.g., Glasgow Coma Scale \\\u003C 13).\n* Craniofacial anomaly or skin condition precluding mask seal.\n* Pregnancy or breastfeeding.\n* Participation in another interventional trial that could interfere with study endpoints.",{"count":349,"type":21},204,[58],"Why: After thyroid or neck surgery, some patients can lose movement of both vocal cords (bilateral vocal-cord paralysis, BVCP). This can make breathing difficult and often leads to an emergency or preventive tracheostomy (\"wind-pipe\") surgery.\n\nWhat: This study will test two simple ways to avoid a tracheostomy:\n\nPre-operative BiPAP sleep training - patients practice sleeping with a non-invasive BiPAP breathing machine for seven nights before surgery so they become comfortable with the mask and pressures.\n\nImmediate post-extubation BiPAP support - the same BiPAP machine is started as soon as the breathing tube is removed in the operating room or recovery area.\n\nHow: Adults (18-80 years) who already have, or are at high risk of getting, BVCP will be randomly assigned to one of four groups in a 2 × 2 design:\n\n• Group 1: training + post-op BiPAP • Group 2: training only • Group 3: post-op BiPAP only • Group 4: standard care (no planned BiPAP).\n\nMain goal: To find out whether either or both BiPAP strategies reduce the need for tracheostomy or re-intubation during the first 7 days after surgery.\n\nWhat participants do: Eligible patients will undergo routine surgery plus the assigned BiPAP plan. Breathing events, comfort, hospital stay, and voice quality will be recorded up to 6 months.\n\nPotential benefit\u002Frisk: BiPAP is non-invasive and already FDA-cleared for home and hospital use, but some people may feel mask discomfort or air leaks. Trained staff will adjust settings and stop BiPAP if serious problems occur.",[353,354,94,355],"Vocal Cord Paralysis, Bilateral","Airway Obstruction, Postoperative","Sleep Apnea, Obstructive",[357,358,359,360,361,362,363,364,365,366],"BiPAP","Non-invasive Ventilation","Continuous Positive Airway Pressure","Peri-operative Airway Management","Tracheostomy Avoidance","Thyroidectomy","Neck Surgery","Glottic Stenosis","Pre-operative Sleep Training","Voice Handicap Index","2025-06-27",{"date":369,"type":38},"2025-06-29",{"date":332,"type":21},{"date":372,"type":21},"2029-12-31",{"name":44,"class":45},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":389,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":400,"locationsCount":46},"100596250","white-cap-intra-operative-parathyroid-tissue-sensor-pts-guided-assessment-of-parathyroid-viability-and-surgical-decision-making-100596250","NCT07043010","WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making","WHITE CAP Trial: Optical Parathyroid Tissue Sensor-Guided Assessment of Parathyroid Viability and Its Impact on Clinical Decision-Making","WHITE CAP-PTS","Inclusion Criteria:\n\n* Age 18 to 75 years, able to give informed consent.\n* Biochemically proven primary hyperparathyroidism (elevated serum calcium and inappropriately high PTH).\n* Pre-operative imaging (sestamibi scan, 4-phase CT, or ultrasound) concordant with a single parathyroid adenoma.\n* Planned minimally invasive parathyroidectomy using near-infrared parathyroid tissue sensor (PTS) guidance.\n\nExclusion Criteria:\n\n* Multiple endocrine neoplasia (MEN 1 or 2) or suspicion of multi-gland disease (\\>1 enlarged gland on imaging).\n* Prior parathyroid or extensive neck surgery causing distorted anatomy.\n* Need for simultaneous total thyroidectomy or other major neck procedure.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n* Pregnancy or breastfeeding.\n* Inability to tolerate general anaesthesia or contraindication to intra-operative PTS imaging.",{"count":169,"type":21},[58],"Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still \"glows\" under a near-infrared parathyroid tissue sensor (PTS). It is unclear whether keeping this tissue in place helps preserve hormone function or whether it leaves behind cells that could become over-active again.\n\nThe WHITE CAP study will compare two common surgical choices:\n\nPreservation strategy - the surgeon removes only the adenoma and leaves the glowing rim of normal tissue untouched.\n\nEn-bloc strategy - the surgeon removes the adenoma together with the glowing rim; if too little parathyroid tissue remains, a small fragment is transplanted into the forearm muscle.\n\nAbout 120 adult patients who have a single parathyroid adenoma will be randomly assigned (like tossing a coin) to one of the two strategies. All operations will use the same FDA-cleared PTS camera that shows the glands in real time without dye or radiation.\n\nThe main question is whether preserving the normal rim lowers the rate of temporary low blood-calcium (numbness, tingling) during the first two days after surgery. The study will also check long-term results-blood calcium and parathyroid hormone (PTH) levels, symptoms, and any return of the disease-over two years.\n\nThe PTS imaging itself is painless and adds only a few minutes to the operation. Risks are the same as for standard parathyroid surgery, and participants can withdraw at any time without affecting their usual care.",[386,387,388,303],"Hyperparathyroidism, Primary","Parathyroid Neoplasms","Parathyroid Adenoma",[390,391,392,393,394,395,396],"Near-Infrared Autofluorescence","Parathyroid Tissue Sensor","Parathyroid Viability","Peri-adenoma Rim Preservation","Intra-operative Imaging","Calcium Homeostasis","PTS Camera",{"date":369,"type":38},{"date":332,"type":21},{"date":372,"type":21},{"name":44,"class":45},{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":409,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":411,"conditions":412,"keywords":416,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":428,"locationsCount":46},"100596248","ret-us-study---ultrasound-based-prediction-of-ret-alterations-and-lateral-neck-metastasis-in-thyroid-cancer-100596248","NCT07042984","RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer","RET-US Cohort: Prospective Evaluation of an AI-Ultrasound Model for Detecting RET Gene Alterations and Predicting Lateral Cervical Lymph-Node Metastasis in Papillary Thyroid Carcinoma","RET-US","Inclusion Criteria:\n\n* Age 18-75 years, able to provide written informed consent.\n* Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma.\n* Planned thyroidectomy (any extent) at a participating institution.\n* Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis.\n\nExclusion Criteria:\n\n* Prior thyroid or major neck surgery.\n* Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck.\n* Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease.\n* Pregnant or breastfeeding.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or other condition that precludes surgery or gene testing.",{"count":410,"type":21},800,"Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or \"AI\" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.\n\nWhat will happen in this study?\n\nAbout 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:\n\n* have a standard pre-operative ultrasound exam (no extra scanning time),\n* give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and\n* allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.\n\nMain goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.\n\nBenefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.",[413,94,414,415],"Papillary Thyroid Carcinoma","RET Proto-Oncogene Mutation","Lymphatic Metastasis",[417,418,419,420,421,422,423],"Ultrasound Radiomics","Artificial Intelligence","RET Fusion","BRAF V600E","Lateral Neck Metastasis","Deep Learning Model","11-Gene Panel","2025-06-21",{"date":369,"type":38},{"date":332,"type":21},{"date":372,"type":21},{"name":44,"class":45},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":167,"enrollmentInfo":436,"targetDuration":4,"studyType":22,"phases":438,"briefSummary":440,"conditions":441,"keywords":442,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":457,"locationsCount":46},"100593742","phase-4-genotype-driven-neoadjuvant-therapy-for-locally-advanced-thyroid-cancer-a-real-world-cohort-study-100593742","NCT07010393","Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 years at enrollment.\n2. Histologically or cytologically confirmed thyroid carcinoma that meets ≥ 1 of the following:\n\n   * Radioactive-iodine-refractory differentiated thyroid carcinoma (DTC)\n   * Medullary thyroid carcinoma (MTC)\n   * Anaplastic or poorly differentiated thyroid carcinoma (ATC\u002FPDTC)\n   * Other locally advanced \u002F metastatic thyroid malignancy deemed incurable by surgery alone.\n3. Disease judged unresectable or entailing prohibitively high-morbidity surgery at baseline by a multidisciplinary thyroid-oncology board.\n4. Documented molecular or immunophenotype qualifying for ≥ 1 study arm:\n\n   * BRAF V600E mutation\n   * RET gene fusion\n   * RET activating point mutation (e.g., M918T)\n   * NTRK1\u002F2\u002F3 fusion\n   * Isolated TERT-promoter mutation with no BRAF\u002FRET\u002FNTRK alterations\n   * Driver-negative \u002F VEGFR-wild type (\"triple-negative\")\n   * PD-L1 expression ≥ 1 % OR progression after prior multi-kinase inhibitor (MKI).\n5. ECOG Performance Status 0-2.\n6. At least one measurable lesion per RECIST v1.1 \u002F iRECIST (MTC with calcitonin\u002FCEA evaluable disease accepted).\n7. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Untreated or symptomatic CNS metastases; patients with treated, stable lesions ≥ 4 weeks and off corticosteroids are eligible.\n2. Pregnant or breastfeeding. Women and men of child-bearing potential must agree to effective contraception during study and for ≥ 120 days after last dose (≥ 180 days for men after dabrafenib\u002Ftrametinib).",{"count":437,"type":21},335,[439],"PHASE4","This multicenter registry tests whether genomically matched neoadjuvant therapy (1-4 cycles tailored to BRAF V600E, RET fusion\u002Fmutation, isolated TERT mutation, triple-negative BRAF\u002FRET\u002FTERT, or ICI ± TKI) can render locally advanced, initially unresectable-or high-morbidity-thyroid cancers operable. The primary endpoint is conversion-to-surgery; key secondaries are R0\u002F1 margin rate and 12-month event-free survival, with propensity-score weighting correcting cohort imbalances. Findings aim to define a precision-guided neoadjuvant standard for down-staging advanced thyroid tumors.",[94],[443,175,444,420,419,445,446,447,448,449,450,451],"Locally Advanced","Real-World Study","VEGF-TKI","Immunotherapy","Conversion Surgery","R0 Resection","Precision Oncology","Real-World Evidence","Conversion Therapy","2025-06-01",{"date":454,"type":38},"2025-06-08",{"date":332,"type":21},{"date":157,"type":21},{"name":44,"class":45},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":46},"100535671","intraoperative-neuromuscular-monitoring-and-its-impact-on-pre--and-postoperative-acoustic-outcomes-in-thyroid-surgery-100535671","NCT06254859","Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery","Inclusion Criteria:\n\n* Age 20-60 years old.\n* Planned conventional unilateral thyroid lobectomy + isthmus resection + central compartment lymph node dissection.\n\nExclusion Criteria:\n\n* History of past head and neck surgeries.\n* Pronunciation system defect and disorder history.\n* History of vocal cord polyps or nodules.\n* History of upper respiratory tract infection in the 2 weeks before surgery or postoperative infection history.\n* History of neurological disorders.\n* Abnormalities in the throat.\n* Preoperative damage to throat morphology or motor function.\n* Preoperative functional voice or language disorders, noticeable hoarseness, or difficulty in pronunciation.\n* Pre- and postoperative laryngoscopic examination showing vocal cord paralysis and arytenoid joint dislocation.\n* Neurological disorders causing abnormal throat function.\n* Patient unable to cooperate with VHI (Voice Handicap Index) assessment and voice spectrum examination.",{"count":89,"type":21},"This study examines the impact of intraoperative recurrent laryngeal nerve monitoring signal changes on the postoperative voice quality of thyroid surgery patients. By analyzing extensive surgical data and postoperative voice recordings, the investigation seeks to identify patterns in the variations of these signals and their correlation with voice quality outcomes. The goal is to enhance clinical understanding and surgical practices, allowing for more precise assessments of nerve function, informed surgical interventions, and improved postoperative patient well-being.",[172,467],"Thyroid Cancer, Papillary",[469,470],"acoustic analysis","thyroid cancer","2025-05-17",{"date":473,"type":38},"2025-05-20",{"date":475,"type":38},"2024-03-01",{"date":477,"type":21},"2025-12-31",{"name":44,"class":45},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":486,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":497,"leadSponsor":499,"locationsCount":46},"100588770","clinical-outcomes-of-indocyanine-green-tracer-using-in-laparoscopic-gastrectomy-with-extended-lymphadenectomy-beyond-d2-for-locally-advanced-gastric-cancer-fuges-30-100588770","NCT06945718","Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)","Prospective Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With D2 Extra-regional Lymph Node Dissection for Locally Advanced Gastric Cancer (FUGES-30)","Inclusion Criteria:\n\nAge from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-\u002F+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent\n\nExclusion Criteria:\n\nWomen during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD\u002FEMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region.\n\nOther malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)\\\u003C50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery",{"count":487,"type":21},760,"Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-\u002F+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.",[225,226],[225,491,492],"Laparoscopic Gastrectomy","Indocyanine Green Tracer","2025-05-05",{"date":495,"type":38},"2025-05-08",{"date":309,"type":21},{"date":498,"type":21},"2030-05-01",{"name":44,"class":45},{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":507,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":509,"conditions":510,"keywords":513,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":46},"100340711","comparison-of-tumor-efficacy-safety-in-laparoscopic-resection-of-gastrointestinal-stromal-tumors-between-favorable-and-unfavorable-site-100340711","NCT03716089","Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site","Prospective Controlled Clinical Trial for Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site（FUGES-016）","Inclusion Criteria:\n\n1. Age between 18 and 75 years old\n2. Primary gastric lesion confirmed pathologically GIST by endoscopic biopsy. Preoperative endoscopy, ultrasound endoscopy or computer tomography, Magnetic resonance suspected GIST, and then postoperative pathology confirmed as the original GIST\n3. Written informed consent\n4. Expected R0 resection by laparoscopy\n5. Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale\n6. ASA (American Society of Anesthesiology) class I to III\n7. Maximum tumor diameter ≤10cm\n\nExclusion Criteria:\n\n1. Pregnant and lactating women\n2. Suffering from a severe mental disorder\n3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)\n4. History of previous gastric surgery (including ESD\u002FEMR for gastric cancer)\n5. Rejection of laparoscopic resection\n6. History of other malignant disease within the past five years\n7. History of unstable angina or myocardial infarction within the past six months\n8. History of a cerebrovascular accident within the past six months\n9. History of continuous systematic administration of corticosteroids within one month\n10. Requirement of simultaneous surgery for another disease\n11. Emergency surgery due to complications (bleeding, obstruction or perforation) caused by gastric cancer\n12. FEV1\\\u003C50% of the predicted values\n13. Maximum tumor diameter \\>10cm",{"count":508,"type":21},250,"Participants with gastrointestinal stromal tumors(GIST) were divided into favorable and unfavorable sites according to the anatomical site of the tumor, and this study aims to validate the overall postoperative morbidity and mortality rates between favorable site receiving laparoscopic resection of GIST and that of unfavorable site under the currently standard surgical therapy.",[511,225,226,512],"GIST of Stomach","Complication",[514,515,516,517,518],"GIST","laparoscopic resection","early complication","mortality","tumor sites","2025-04-07",{"date":521,"type":38},"2025-04-08",{"date":523,"type":38},"2018-10-11",{"date":525,"type":21},"2027-04-01",{"name":44,"class":45},{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":534,"minAge":17,"maxAge":218,"enrollmentInfo":535,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":4},"100570734","albumin-bound-paclitaxeldalpiciclib-and-ai-in-er-low-1-10-her2-abc-100570734","NCT06711094","Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABC","Single-arm,Exploratory Clinical Study of Albumin-bound Paclitaxel Combination With Dalpiciclib and AI in the Treatment of ER-Low (1%-10%), HER2-negative Advanced Breast Cancer","Inclusion Criteria:\n\n1. Postmenopausal or premenopausal\u002Fperimenopausal women ≥18 years old and ≤75 years old, meeting one of the following criteria: a) prior bilateral oophorectomy, or ≥60 years old; Or b) age \\\u003C60, natural postmenopausal status (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months without other pathological or physiological causes), E2 and FSH at postmenopausal levels; Or c) premenopausal or perimenopausal women may also be enrolled, but must be willing to receive LHRH agonist therapy during the study period.\n2. Female breast cancer patients diagnosed by pathology as ER-Low positive (1%-10%) and HER2-negative have evidence of focal recurrence or metastasis, and are not suitable for surgical resection or radiotherapy for the purpose of cure. a) Low ER expression was defined as: the proportion of tumor cells with positive staining accounted for ≥ 1% and ≤10% of all tumor cells (confirmed by investigators in the study center); b) HER2 negative is defined as a standard immunohistochemical (IHC) test of 0\u002F1+; Or the IHC test is 2+ and the ISH test is negative (reviewed and confirmed by the investigator at the study center).\n3. Have not previously received any systemic anticancer therapy for recurrent or metastatic disease.\n4. The physical status score of the Eastern Cancer Collaboration Group (ECOG) was 0-1.\n5. Measurable lesions or bone metastases only (including osteolytic lesions or mixed osteolytic\u002Fosteoblastic lesions) that meet RECIST 1.1 criteria.\n6. Adequate organ and bone marrow function.\n7. Women of reproductive age must have a negative serum pregnancy test within 7 days prior to enrollment and be willing to use a medically approved highly effective contraceptive during the study period and within 3 months after the last study drug administration.\n8. Remission of all acute toxic reactions from previous antitumor therapy to grade 0-1 (according to NCICTCAE version 5.0) or to the level specified in the inclusion\u002Fexclusion criteria. The exception is other toxicities, such as hair loss, that researchers believe do not pose a safety risk to patients.\n\nExclusion Criteria:\n\n1. Previous pathological examination diagnosed HER2-positive breast cancer.\n2. Inflammatory breast cancer.\n3. Disease progression or recurrence during prior adjuvant therapy or within 12 months after completion of adjuvant therapy.\n4. Patients judged unsuitable for chemotherapy by the investigators. This includes symptomatic, advanced patients who have spread to the viscera and are at risk of developing life-threatening complications in the short term (including patients with uncontrolled exudation \\[thoracic, pericardial, abdominal\\], pulmonary lymphangitis, and more than 50% liver involvement).\n5. Patients with symptomatic active brain metastases or meningeal metastases were confirmed by cranial CT or MRI.\n6. Previous treatment with any CDK4\u002F6 inhibitors.\n7. Major surgery, chemotherapy, radiation therapy, any investigational drug, or other anti-cancer treatment within 2 weeks prior to study entry.\n8. Any other malignant tumor diagnosed within 3 years prior to study entry, except for non-melanoma skin cancer, basal cell or squamous cell skin cancer, or cervical carcinoma in situ after radical treatment.\n9. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBV DNA ≥1000 IU\u002Fml), hepatitis C (HCV antibody positive and HCV-RNA above the lower detection limit of analytical methods), or co-infection with hepatitis B and hepatitis C.\n10. Within 6 months prior to entering the study, the following situations occurred: Myocardial infarction, severe\u002Funstable angina pectoris, NYHA grade 2 or higher cardiac insufficiency, persistent arrhythmias ≥ grade 2 (according to NCI CTCAE 5.0), atrial fibrillation of any grade, coronary\u002Fperipheral artery bypass surgery, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism).\n11. Severe infection within 4 weeks prior to the first dose (e.g. intravenous antibiotic, antifungal, or antiviral medication required according to clinical practice), or unexplained fever \\>38.5°C during screening\u002Fprior to the first dose.\n12. Inability to swallow, intestinal obstruction, or other factors affecting the administration and absorption of medications.\n13. Known allergy to albumin-bound paclitaxel, letrozole, anastrozole, Metrotan, LHRH agonists (goserrelin, leprerelin), Darcilil, or any excipients.\n14. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n15. Known history of psychotropic substance abuse or drug use.\n16. The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participation in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.","FEMALE",{"count":536,"type":21},52,[58],"This is a prospective, single-arm, single-center, open, exploratory clinical study.. Screening for histopathologically confirmed recurrent or metastatic ER-Low positive (1%-10%) and HER2-negative breast cancer patients who meet the inclusion criteria and have not previously received any systemic anticancer therapy for advanced disease, He was treated with albumin-bound paclitaxel in combination with Dalpiciclib and AI.",[540],"HR+\u002FHER2- Advanced Breast Cancer","2024-11-28",{"date":543,"type":38},"2024-12-02",{"date":545,"type":21},"2025-01-01",{"date":547,"type":21},"2028-12-30",{"name":44,"class":45},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":22,"phases":557,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":46},"100554406","clinical-application-of-ai-assisted-ultrasound-technology-in-the-preoperative-evaluation-of-thyroid-cancer-100554406","NCT06498674","Clinical Application of AI-assisted Ultrasound Technology in the Preoperative Evaluation of Thyroid Cancer","Inclusion Criteria:\n\n* Patients with preoperative pathological confirmation of thyroid malignant tumors undergoing surgical treatment.\n* Patients with benign thyroid tumors, such as thyroid adenomas causing compressive symptoms, undergoing surgical treatment.\n* Patients with complete and high-quality traditional two-dimensional color ultrasound images.\n* Complete postoperative pathology reports.\n* Willingness to participate in this clinical trial and signing of informed consent.\n\nExclusion Criteria:\n\n* Patients with a history of neck surgery or radiotherapy.\n* Patients with a history of malignant tumors in other parts of the body.\n* Patients with thyroid dysfunction.\n* Incomplete or poor-quality traditional two-dimensional color ultrasound images.\n* Incomplete postoperative pathology reports.\n* Refusal to participate in this clinical trial.",{"count":556,"type":21},300,[58],"This study aims to explore the application of AI-assisted ultrasound technology in the preoperative assessment of thyroid cancer. Traditional ultrasound examination data from thyroid cancer patients will be collected, and AI systems will be utilized to detect and diagnose thyroid nodules and lymph nodes. In cases where there is disagreement between the two-dimensional ultrasound and AI system results, further confirmation will be sought through biopsy. Subsequently, pathological results will serve as the \"gold standard\" for comparison between the AI system and traditional ultrasound examination results, assessing their accuracy and reliability. Through this research endeavor, a more accurate and reliable method for preoperative assessment of thyroid cancer is aspired to be offered, thereby supporting clinical decision-making and paving the way for novel applications of AI in the field of medical imaging diagnosis.",[172],[172,418,561,562],"Ultrasound","Preoperative Assessment","2024-09-24",{"date":565,"type":38},"2024-09-26",{"date":567,"type":38},"2024-07-01",{"date":569,"type":21},"2025-06-30",{"name":44,"class":45},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":16,"minAge":578,"maxAge":18,"enrollmentInfo":579,"targetDuration":4,"studyType":22,"phases":581,"briefSummary":582,"conditions":583,"keywords":585,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":46},"100559760","phase-1-chimeric-natural-killer-receptor-universal-t-cells-for-refractory-gvhd-100559760","NCT06568328","Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD","A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CNK-UT Cells to Treat the Patients With Steroid-refractory\u002FResistant or Steroid-dependent GVHD","Inclusion Criteria:\n\n1. Aged 1\\~70 years, male or female;\n2. Participants diagnosed with grade II\\~IV steroid-refractory\u002Fresistant or steroid-dependent GVHD after allogeneic hematopoietic stem cell transplantation who have failed treatment with ruxolitinib or at least one other second-line medication, or who are intolerant to these medications.\n3. ECOG physical status score 0\\~3;\n4. Estimated life expectancy \\> 12 weeks;\n5. Female participants of childbearing age must undergo a serum or urine pregnancy test before enrollment, and the results must be negative, and agree to take acceptable measures to minimize the possibility of pregnancy during the trial; For female participants of childbearing age or male participants whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the study and for at least 6 months following the last dose of the study cells infusion.\n6. Participants voluntarily participate in clinical trial; Understand and know this study, sign an informed consent form, and be willing to follow all experimental procedures.\n\nExclusion Criteria:\n\n1. Suffering from malignant tumors or diagnosed within 5 years before enrollment, excluding radical skin basal cell carcinoma, skin squamous cell carcinoma, thyroid cancer, breast cancer (ductal carcinoma in situ) and \u002F or radical resection of carcinoma in situ.\n2. Participants with a history of organ transplantation;\n3. Participants who have previously undergone more than one allogeneic hematopoietic stem cell transplantation.\n4. Uncontrolled hypertension as determined by principal investigator, a history of hypertensive crisis or hypertensive encephalopathy; symptomatic congestive heart failure (New York Heart Association classification III-IV); symptomatic or poorly controlled arrhythmias; a history of congenital long QT syndrome or a corrected QT interval (QTc) \\> 500 ms at screening (calculated using the Fridericia method)..\n5. Systemic diseases deemed unstable by principal investigator include, but are not limited to, severe pulmonary, hepatic, renal, or metabolic disorders that require pharmacological intervention (excluding complications related to allogeneic hematopoietic stem cell transplantation).\n6. Active pulmonary tuberculosis (TB), who is receiving anti-tuberculosis treatment or has received anti-tuberculosis treatment within 1 year before enrollment; human immunodeficiency virus (HIV) infection, known syphilis infection.\n7. Severe infections that are active or poorly controlled clinically.\n8. Participants who have received treatment from other clinical trials within 12 weeks prior to the initiation of the study.\n9. Participants who have previously used any gene therapy products prior to the initiation of the study.\n10. Allergic to components of CNK-UT injection.\n11. Participants suffer from known mental or substance abuse disorders, which may interfere with their ability to comply with research requirements.\n12. Women who are pregnant or breastfeeding, as well as male or female participants who have planned for birth within 1 year after receiving medication.\n13. Uncontrolled\u002Funcorrectable metabolic disorders or other non-malignant organ diseases or systemic diseases or secondary reactions to cancer, which can lead to higher medical risk and\u002For uncertainty in survival assessments.\n14. Other situations that the participant is identified by the investigator as unsuitable to participate in the study.","1 Year",{"count":580,"type":21},17,[143],"This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory\u002Fresistant or steroid-dependent GVHD.",[584],"Graft vs Host Disease",[586,587],"Chimeric natural killer receptor universal T-cells","steroid-refractory\u002Fresistant or steroid-dependent GVHD","2024-08-22",{"date":590,"type":38},"2024-08-23",{"date":592,"type":21},"2024-09-01",{"date":594,"type":21},"2026-08-31",{"name":44,"class":45},{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":603,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":313},"100525914","an-interventional-left-ventricular-assist-system-for-cardiogenic-shock-100525914","NCT06127927","An Interventional Left Ventricular Assist System for Cardiogenic Shock","Evaluation the Efficacy and Safety of an Interventional Left Ventricular Assist System for Hemodynamic Support in Patients With Cardiogenic Shock: A Prospective, Multicenter, Single-group Target Value Study of Sustained","For Pre-trial Phase\n\nInclusion Criteria:\n\n1. Age 18-75 years old;\n2. Refractory cardiogenic shock as determined by the cardiac MDT expert group; The criteria for refractory cardiogenic shock are: despite adequate doses of two vasoactive drugs and treatment of the underlying cause, there is still evidence of tissue hypoperfusion;\n3. The subject can understand the purpose of the trial, voluntarily participate and sign the written informed consent form reviewed and approved by the ethics committee; the subject agrees to complete the follow-up in accordance with the protocol requirements.\n\nExclusion Criteria:\n\n1. Right heart failure that meets any of the following conditions:\n\n   a Central venous pressure-capillary wedge pressure ≥10mmHg; b Central venous pressure-pulmonary artery diastolic pressure ≥10mmHg; c Cardiac tamponade.\n2. Any peripheral vascular disease that prevents the placement of the trial device;\n3. Left or right ventricular thrombus;\n4. Aortic valve regurgitation, echocardiographic grade ≥2+;\n5. Aortic valve stenosis, valve area ≤1.5cm2;\n6. Aortic valve calcification;\n7. Presence of mechanical aortic valve;\n8. Hypertrophic or obstructive cardiomyopathy;\n9. Untreated ventricular septal or atrial septal defect;\n10. Patent foramen ovale;\n11. Mechanical complications of acute myocardial infarction;\n12. Presence of hereditary spherocytosis, hereditary elliptocytosis, autoimmune hemolytic anemia or other diseases that cause hemolysis;\n13. Cardiopulmonary resuscitation lasting more than 15 minutes within 24 hours before catheter pump implantation;\n14. Ventricular tachycardia or ventricular fibrillation is ineffective with drug treatment;\n15. Renal failure, serum creatinine ≥309.4umol\u002Fl or blood urea nitrogen ★ ≥35.7mmol\u002Fl);\n16. Liver failure (total bilirubin ≥85.5umol\u002Fl);\n17. Allergy or intolerance to heparin;\n18. Presence of any cardiac assist device;\n19. Presence of active systemic infection;\n20. Refusing to sign the informed consent form or failing to complete follow-up as required by the protocol;\n21. Pregnant or lactating women, female subjects with potential fertility but unable or unwilling to use effective contraceptive measures during the study;\n22. Subjects who have participated in other clinical trials within 3 months or are currently participating in other clinical trials;\n23. Other situations that the investigator believes are not suitable for clinical trials.\n\nFor Formal Research Phase\n\nInclusion Criteria:\n\n1. Age 18-75 years old;\n2. Low cardiac output syndrome or increased filling pressure after regular continuous pumping of 1 high-dose or 2 medium-dose inotropic drugs within 48 hours after cardiopulmonary bypass was removed during cardiac surgery. The specific criteria are as follows;\n\nThe drugs, doses and time of 1 high-dose or 2 medium-dose inotropic drugs are as follows:\n\nEpinephrine: medium dose (\\\u003C0.03 μg\u002Fkg\u002Fmin), continuous pumping ≥15 minutes High dose (≥0.03 μg\u002Fkg\u002Fmin), continuous pumping ≥15 minutes; Dobutamine: medium dose (\\\u003C5μg\u002Fkg\u002Fmin), continuous pumping ≥15 minutes High dose (≥5μg\u002Fkg\u002Fmin), continuous pumping ≥15 minutes; Milrinone: medium dose (\\\u003C0.3 μg\u002Fkg\u002Fmin), continuous pumping ≥120 minutes High dose (≥0.3 μg\u002Fkg\u002Fmin), continuous pumping ≥120 minutes; Low cardiac output syndrome: cardiac index 1.3≤CI≤2.2 L\u002Fmin\u002Fm2;\n\nIncreased filling pressure: pulmonary capillary wedge pressure:\n\n20≤PCWP≤30mmHg or pulmonary artery systolic pressure: 25≤PAP≤35mmHg 3) The subject can understand the purpose of the trial, voluntarily participate and sign the informed consent form reviewed and approved by the ethics committee; the subject agrees to complete the follow-up in accordance with the protocol requirements.\n\nExclusion Criteria:\n\n1. Right heart failure that meets any of the following conditions:\n\n   1. Central venous pressure-capillary wedge pressure ≥10mmHg;\n   2. Central venous pressure-pulmonary artery diastolic pressure ≥10mmHg;\n   3. Cardiac ascites.\n2. Any peripheral vascular disease that prevents the placement of the trial device;\n3. Left or right ventricular thrombus;\n4. Aortic valve regurgitation, echocardiographic grade ≥2+;\n5. Aortic valve stenosis, valve area ≤1.5cm2;\n6. Presence of mechanical aortic valve;\n7. Hypertrophic or obstructive cardiomyopathy;\n8. Untreated ventricular septal or atrial septal defect;\n9. Patent foramen ovale;\n10. Mechanical complications of acute myocardial infarction;\n11. Suffering from diseases that cause increased blood cell fragility or hemolysis;\n12. Cardiopulmonary resuscitation lasting more than 15 minutes within 24 hours before catheter pump implantation;\n13. Sustained or non-sustained ventricular tachycardia or ventricular fibrillation that is unresponsive to drug treatment;\n14. Renal failure, serum creatinine ≥3.5mg\u002Fdl or blood urea nitrogen ≥100mg\u002Fdl;\n15. Liver failure, total bilirubin ≥5mg\u002Fdl;\n16. Allergy or intolerance to heparin;\n17. Other cardiac assist devices other than IABP have been implanted;\n18. Active systemic infection;\n19. Refuse to sign the informed consent form or fail to complete follow-up as required by the protocol;\n20. Pregnant or lactating women, female subjects with potential fertility but unable or unwilling to use effective contraceptive measures during the study;\n21. Subjects who are participating in other clinical trials and have not yet reached the endpoints of the trial;\n22. Other situations that the investigator believes are not suitable for clinical trials.",{"count":322,"type":21},[58],"Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.",[607],"Cardiogenic Shock","2024-07-04",{"date":610,"type":38},"2024-07-08",{"date":612,"type":38},"2023-11-08",{"date":614,"type":21},"2025-12-08",{"name":44,"class":45},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":16,"minAge":623,"maxAge":320,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":625,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":46},"100553968","a-triple-branched-stent-graft-for-aute-debakey-type-i-dissection-surgery-100553968","NCT06492980","A Triple-branched Stent Graft for Aute Debakey Type I Dissection Surgery","Safety and Effectiveness of a Triple-branched Stent Graft for Arch Repair During Open Aute Debakey Type I Dissection Surgery - a Randomized Controlled Multicenter Clinical Trial","Inclusion Criteria:\n\n1. Patients with acute type I aortic dissection who need arch repair;\n2. Aged ≥20 years and ≤65 years;\n3. Acute phase, with onset within 14 days before surgery;\n4. Subjects who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to accept follow-up.\n\nExclusion Criteria:\n\n1. The presence of anatomical variations, such as aortic arch malformation, aortic coarctation; common origin of the innominate artery and the left common carotid artery, aberrant right subclavian artery, abnormal origin of the left conical artery, stenosis or distortion of the branch arteries; and the diameter of the aortic arch and branch artery diameters do not match the specifications of the test device;\n2. Dissection is secondary to a history of aortic treatment, Marfan syndrome, etc.\n3. Aortic lesions and branch artery lesions caused by acute type I aortic dissection, including aortic pre-rupture, branch artery rupture, branch artery occlusion, and severe ischemic complications caused by poor organ perfusion, such as myocardial ischemia, stroke (ischemic brain injury), paraplegia (spinal artery ischemia), mesenteric artery ischemia, renal artery dysplasia, etc.\n4. Severe infectious lesions that are not controlled;\n5. Patients who need to receive other concomitant treatments, such as severe hypertension, chronic obstructive pulmonary disease, coronary heart disease, chronic kidney disease and other serious underlying lesions that require long-term treatment;\n6. Patients with other life-threatening lesions, such as advanced malignant tumors, and whose expected survival time is less than one year;\n7. Patients with other lesions in the heart and aorta (patients with other heart diseases that require concurrent heart surgery, such as coronary heart disease, mitral valve disease, tricuspid valve disease, etc.), who are not suitable for stent interventional treatment, such as peripheral vascular disease and blood disease;\n8. Subjects who have participated in other drug or device clinical trials and have not reached the primary study endpoint; and pregnant women.","20 Years",{"count":245,"type":21},[58],"Prospective, multicenter, randomized controlled clinical trial plan to evaluate the effectiveness and safety of intraoperative stent system in the treatment of acute type I aortic dissection",[628],"Acute Aortic Dissection","2024-07-02",{"date":631,"type":38},"2024-07-09",{"date":633,"type":38},"2023-10-27",{"date":635,"type":21},"2025-10-10",{"name":44,"class":45},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":218,"enrollmentInfo":645,"targetDuration":4,"studyType":22,"phases":647,"briefSummary":648,"conditions":649,"keywords":650,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":46},"100528471","phase-3-3d-4k-icg-laparoscopic-gastrectomy-for-gastric-cancer-100528471","NCT06161207","3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer","Prospective Randomized Controlled Trials on Clinical Outcomes of Indocyanine Green Tracer Using in 3D Plus Ultra High Resolution Laparoscopic Gastrectomy With Lymph Node Dissection for Locally Advanced Gastric Cancer","3D-4K-ICG","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy\n3. cT2-4a, N-\u002F+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition\n4. No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations\n5. Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale\n6. ASA (American Society of Anesthesiology) class I to III\n7. Written informed consent\n\nExclusion Criteria:\n\n1. Women during pregnancy or breast-feeding\n2. Severe mental disorder\n3. History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)\n4. History of previous gastric surgery (including ESD\u002FEMR for gastric cancer)\n5. Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging\n6. Other malignant disease within the past 5 years\n7. History of previous neoadjuvant chemotherapy or radiotherapy\n8. History of unstable angina or myocardial infarction within past six months\n9. History of cerebrovascular accident within past six months\n10. History of continuous systematic administration of corticosteroids within one month\n11. Requirement for simultaneous surgery for other disease\n12. Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer\n13. FEV1 (forced expiratory volume in one second)\\\u003C50% of predicted values\n14. Diffuse invasive gastric cancer\n15. History of an iodine allergy\n16. Patients who declined laparoscopic surgery",{"count":646,"type":21},702,[222],"Patients with locally advanced gastric adenocarcinoma (CT2-4a N-\u002F+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.",[225,226],[492,491,225,651,652],"Ultra High Resolution","3D","2024-06-20",{"date":655,"type":38},"2024-06-24",{"date":657,"type":38},"2023-01-03",{"date":659,"type":21},"2029-01-01",{"name":44,"class":45},""]